Principal Scientist Anders Cai Holm Hansen explains how CDMO AGC Biologics uses its global, single-use network and a strategy ...

Sartorius Stedim Biotech (SSB) said today it will integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion ...

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, ...

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry today announced the launch of the ambr ® 250 high throughput (ht) perfusion, a new automated ...

Developing a new therapeutic molecule is a complex and expensive process with a high risk of failure at each step. Research suggests that aggregate costs per commercialized drug (including failures) ...

The biopharmaceutical and biotech industries face mounting challenges in regulated environments, including rising drug development costs, strict regulatory demands, and the need for scalable, ...

The demand for producing therapeutic recombinant proteins is generating a renewed interest in perfusion cell culture technologies, leading to the development of cell culture media that can support ...

SAN ANTONIO -- Oct. 8, 2019 -- Southwest Research Institute has received new funding from the Medical Technology Enterprise Consortium (MTEC) and the Food and Drug Administration (FDA) to use an ...

However, LV manufacturing methods require upgrading to meet the current demands. Early phase clinical trials require extensive amounts of LVs, 8 which are still mostly produced by non-standardized, ...

If the cultivated meat industry were to set the ambitious target of supplying 10% of the global meat market, how much product would be required? How many factories, containing how many bioreactors, ...